Since the first approval of Fulphila in 2018, the pegfilgrastim market has added competitors and steadily decreased in net price through 2022. The latest Samsung Bioepis Biosimilar Market Report indicates that pegfilgrastim biosimilar marketshare is up to 85% in year 7. And two products account for 73% of that total. The picture has changed considerably … Continue reading Why the Distortion in the Pegfilgrastim Market?